Intuitive Surgical, Inc.
0R29.L
London Stock Exchange438.15
USD
+16.27
- -
Intuitive Surgical, Inc.
0R29.L
(London Stock Exchange)
Recent
price
438.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Intuitive Surgical, Inc. (Nasdaq: ISRG; LSE: 0R29) develops, manufactures and markets robotic-assisted surgical systems and related instruments and services for minimally invasive procedures worldwide. The company offers the da Vinci surgical systems, including da Vinci 5, da Vinci Xi, da Vinci X, da Vinci SP and earlier generations, comprising an ergonomic surgeon console, patient-side cart with interactive arms, high-definition 3D vision system and wristed instruments for procedures in urology, gynecology, general surgery, thoracic surgery, colorectal surgery, head and neck surgery and other specialties; the Ion endoluminal robotic bronchoscopy system for lung biopsy and diagnostic procedures; digital solutions such as My Intuitive platform for data analytics, surgical insights and performance optimization; and related accessories, disposable instruments, training, maintenance and support services. Headquartered in Sunnyvale, California and founded in 1995, Intuitive Surgical operates globally across North America, Europe, Asia-Pacific and other regions, serving hospitals, surgical teams and healthcare systems. Recent developments include the rollout of the da Vinci 5 system with placements reaching 362 units in 2024 and FDA-cleared software upgrades in September 2025 featuring Force Gauge, In-Console Video Replay and Network CCM for enhanced surgeon decision-making; CE Mark approval for da Vinci 5 in Europe; strong Q3 2025 procedure growth of 19% for da Vinci and 52% for Ion; expanded da Vinci system placements totaling 1,526 units in 2024, including increased usage-based operating leases; and ongoing investments in AI-driven analytics and digital tools alongside partnerships such as with Siemens Healthineers for imaging integration.